14 Jun 2024

Press & news

FluoGuide develops surgical solutions that is expected to reduce suffering for the patient and increases the likelihood of cure as well as reducing costs for the health care system.

New - New exchange: Nasdaq First North

FluoGuide is moving from Spotlight to Nasdaq First North. Shareholders are strongly encouraged to make sure they will be able to freely trade their shares in the future.

FluoGuide appoints new Certified Adviser

Press release

March 18, 2021

Copenhagen, Denmark, 18 March 2021 – FluoGuide A/S (“FluoGuide” or the “Company) appoints Svensk Kapitalmarknadsgransking AB as its new Certified Adviser.


FluoGuide appoints Svensk Kapitalmarknadsgransking AB (SKMG), as its new Certified Adviser (CA), from 1. April 2021.

Västra Hamnen Corporte Finance AB will continue as CA until SKMG takes over the responsibility 1. April 2021.

For further information, please contact:
Henrik Moltke, CFO
FluoGuide A/S
Phone: +45 22 44 54 04

Certified Adviser
Västra Hamnen Corporte Finance AB
Phone: +46 40 200 250

Certified Adviser (from 1. april 2021)
Svensk Kapitalmarknadsgransking AB
Phone: +46 70 755 95 51


About FluoGuide
FluoGuide’s primary focus is to maximize surgical outcomes in oncology. The Company’s lead product, FG001, is designed to improve surgical precision by illuminating cancer cells intraoperatively. The improved precision enabled by FluoGuide’s products has a dual benefit – it reduces both the frequency of local recurrence post-surgery and lessens surgical sequelae. Ultimately, the improved precision will improve a patient’s chance of achieving a complete cure and will lower system-wide healthcare costs. The Company is conducting a proof-of-concept clinical study (phase I/II) to demonstrate the effect of FG001 in patients with high grade glioma. FluoGuide is listed on Nasdaq First North Growth Market Stockholm under the ticker “FLUO”.